RFPs: Improving Dermatologic Immunology, Inflammation, and Allergy Care (Japan)

The Japanese Society for Cutaneous Immunology and Allergy (JSCIA), in partnership with Pfizer, invites proposals from eligible institutions to improve dermatologic immunology, inflammation, and allergy care in Japan. Grants of up to JPY 5,000,000 are available for projects spanning 1–3 years, focusing on professional education, multidisciplinary care, and the implementation of best clinical practices to enhance patient care quality.

Overview of the JSCIA-Pfizer Grant Program

This initiative supports projects that aim to improve the clinical management of skin immune, inflammatory, and allergic conditions through structured education, skill-building, and care optimization in healthcare settings. The program emphasizes translating scientific knowledge into practical improvements in patient care, excluding clinical trials or guideline development.

Key Objectives

• Standardize clinical practices in dermatologic immunology, inflammation, and allergy care.

• Enhance professional education and training for healthcare providers.

• Foster multidisciplinary care teams and inter-institutional collaboration.

• Translate scientific evidence into practical improvements in patient outcomes.

Eligible Activities

Projects may include:

• Practical clinical skill training programs for healthcare professionals.

• Establishment or strengthening of multidisciplinary care teams.

• Development of educational networks across hospitals or regional medical institutions.

• Collaboration initiatives that improve clinical practice based on current scientific knowledge.

Exclusions:

• Clinical research, epidemiological studies, trials of diagnostic or therapeutic agents, and clinical guideline development.

Who is Eligible?

Eligible applicants include:

• Medical and dental schools.

• Hospitals and professional medical associations.

• Foundations and non-profit health organizations.

Ineligible applicants:

• Individual practitioners, small private clinics, or for-profit entities.

Collaboration across institutions is allowed, but the lead organization must retain primary responsibility for the project.

Funding Details

• Grant Amount: Up to JPY 5,000,000 per project.

• Total Program Budget: Approximately JPY 10,000,000.

• Project Duration: 1–3 years (May 1, 2026 – April 30, 2029).

• Funding Coverage: Direct and indirect costs; institutional overhead capped at 28%.

• Exclusions: Capital expenses such as software or equipment purchases. Equipment hire or leasing is permitted.

How to Apply / Submission Process

1. Prepare Proposal: Include project goals, needs assessment, target audience, project design, innovation, evaluation plan, timeline, and budget in Japanese yen.

2. Submit Online: Applications must be submitted via the designated JSCIA online portal.

3. Grant Agreement: If selected, sign a formal grant agreement with JSCIA.

4. Reporting and Presentation: Successful projects must provide periodic progress reports and present results at the annual JSCIA meeting.

Why It Matters

• Strengthens dermatologic care quality in Japan.

• Enhances professional expertise in managing inflammatory and allergic skin conditions.

• Promotes collaboration and knowledge sharing across institutions.

• Improves patient outcomes through evidence-informed clinical practices.

Tips for Successful Applications

• Highlight innovative approaches to clinical training and care improvement.

• Demonstrate collaboration and capacity building across multiple institutions.

• Ensure clear and measurable evaluation metrics for the proposed activities.

• Focus on practical, hands-on solutions rather than research or trials.

• Stay within the funding limits and ensure compliance with cost guidelines.

FAQ

1. What is the maximum funding per project? Up to JPY 5,000,000.
2. Can individual practitioners apply? No, only eligible institutions may apply.
3. Are clinical trials or research studies eligible? No, these are explicitly excluded.
4. What is the project duration? Between 1 and 3 years (May 2026 – April 2029).
5. Can equipment costs be covered? Only hire or leasing of equipment is allowed; capital purchases are not covered.
6. Is collaboration with other institutions allowed? Yes, but the lead organization must retain primary responsibility.
7. Are progress reports required? Yes, and results must be presented at the JSCIA annual meeting.

Conclusion

The JSCIA-Pfizer grant program provides a strategic opportunity for medical institutions in Japan to enhance dermatologic immunology, inflammation, and allergy care. By funding education, professional training, and multidisciplinary collaboration, this initiative strengthens clinical practice, promotes evidence-based care, and improves patient outcomes across the country.